We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel...
Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE, United Kingdom, Aug. 26, 2024 (GLOBE...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.69 | 8.80102040816 | 7.84 | 8.79 | 7.8 | 277786 | 8.12720259 | CS |
4 | 2.45 | 40.2960526316 | 6.08 | 8.79 | 5.65 | 345272 | 7.34369907 | CS |
12 | 0.46 | 5.70012391574 | 8.07 | 9.21 | 5.51 | 254139 | 7.33894926 | CS |
26 | 5.82 | 214.760147601 | 2.71 | 11.55 | 2.52 | 571655 | 5.69155333 | CS |
52 | 5.87 | 220.676691729 | 2.66 | 11.55 | 2.35 | 292458 | 5.63406887 | CS |
156 | -9.46 | -52.5847693163 | 17.99 | 20.91 | 2.21 | 134773 | 5.82553458 | CS |
260 | -7.72 | -47.5076923077 | 16.25 | 29.69 | 2.21 | 141250 | 7.01462972 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions